| Literature DB >> 35284615 |
Sandra Chyderiotis1, Jonathan Sicsic2, Nathalie Thilly3, Judith E Mueller1,4.
Abstract
Background: We previously conducted a single-profile discrete choice experiment to elicit preferences of adolescents around HPV vaccine communication, finding that only half of participants made variable choices (non-uniform respondents) from which preferences were elicited. In this paper we provide a framework to evaluate post-choice certainty information to elicit preferences even among respondents who uniformly accepted (serial demanders) or refused (serial non-demanders) hypothetical vaccination scenarios.Entities:
Keywords: Adolescents; Choice certainty; HPV; Vaccination; Vaccine eagerness; discrete choice experiment
Year: 2022 PMID: 35284615 PMCID: PMC8914374 DOI: 10.1016/j.ssmph.2022.101058
Source DB: PubMed Journal: SSM Popul Health ISSN: 2352-8273
Impact of attributes on vaccine eagerness (range −10 to +10) in the full study sample. Non-representative sample of 1458 adolescents in France, January–March 2020.
| Vaccine eagerness | Without individual characteristics | Parsimonious model | ||
|---|---|---|---|---|
| Coefficient | 95% CI | Coefficient | 95% CI | |
| Disease | ||||
| Respiratory disease | ref | ref | ||
| Cancer | 0.36* | [0.03,0.69] | 0.35* | [0.04,0.67] |
| Genital warts | −0.12 | [-0.42,0.18] | −0.14 | [-0.45,0.17] |
| Safety | ||||
| No side effect | ref | ref | ||
| Scientific surveillance | −0.25* | [-0.50,-0.00] | −0.22 | [-0.48,0.04] |
| Safety other countries | −2.08*** | [-2.29,-1.86] | −2.07*** | [-2.32,-1.83] |
| Benefit/risk | −2.18*** | [-2.61,-1.75] | −2.20*** | [-2.64,-1.76] |
| Indirect protection | ||||
| Protects only you | ref | ref | ||
| Protects other people | 0.32*** | [0.15,0.50] | 0.30** | [0.10,0.49] |
| Elimination | 0.47*** | [0.23,0.71] | 0.46*** | [0.22,0.70] |
| Coverage | ||||
| Not enough | ref | ref | ||
| Already a third | 0.66** | [0.24,1.08] | 0.67** | [0.24,1.09] |
| Most adolescents | 1.16*** | [0.85,1.47] | 1.17*** | [0.86,1.47] |
| Other countries 80% | 1.04*** | [0.65,1.42] | 1.03*** | [0.61,1.46] |
| Middle school | ref | |||
| School 1 | 1.62*** | [1.25,1.99] | ||
| School 2 | −0.26* | [-0.50,-0.02] | ||
| School 3 | 1.64*** | [1.35,1.93] | ||
| School 4 | 1.30*** | [1.05,1.54] | ||
| School 5 | ||||
| In favour of vaccination (binary) | ||||
| Disagree or I do not know | ref | |||
| Agree or strongly agree | 3.54*** | [2.79,4.29] | ||
| Education level of the parents | ||||
| Inferior or equal to French baccalaureat | ref | |||
| Superior to French baccalaureat for at least one parent | −0.11 | [-0.49,0.28] | ||
| I do not know, non-applicable | −0.56** | [-0.95,-0.16] | ||
| Language spoken with parents | ||||
| Only French | ref | |||
| Also another language | −0.77** | [-1.35,-0.20] | ||
| ‘‘It is useful to get vaccinated” | ||||
| Disagree | ref | |||
| Agree | 3.15*** | [2.29,4.01] | ||
| I do not know | −0.23 | [-1.87,1.41] | ||
| ‘‘Do you find it easy to get trustworthy information on vaccination?” | ||||
| Difficult | ref | |||
| Easy | 0.81* | [0.08,1.54] | ||
| I do not know | 0.61 | [-0.26,1.49] | ||
Parsimonious model obtained after adding significant individual characteristic variables at p < 0.02 then using a backward stepwise approach at p < 0.05.
*: p-value<0.05; **: p-value<0.01; ***: p-value<0.001.
Attributes and levels of the discrete choice experiment.
| Attributes | Levels (labels) | Levels (short definition) |
|---|---|---|
| Respiratory disease | The vaccine can protect against a disease with high fever and breathlessness. | |
| Cancer | The vaccine can protect against a cancer, which could occur 20 years from now. | |
| Genital warts | The vaccine can protect against genital warts. | |
| No side effect | The vaccine does not cause serious side effects. | |
| Scientific surveillance | The vaccine’s safety has been monitored for more than 10 years worldwide. No serious side effect has been scientifically confirmed. | |
| Safety other countries | In countries where most adolescents are vaccinated, the risk of a serious side effect that could be due to vaccination has not increased. | |
| Benefit/risk | The vaccine can only on rare occasions cause a serious side effect, but the benefits from vaccination are much greater than its risk. | |
| Protects only you | The vaccine protects only you. | |
| Protects others | By getting vaccinated, you can avoid transmitting the infection to other persons. | |
| Elimination | By vaccinating most young people of your age, one can make the disease disappear from the population. | |
| Not enough | Not enough adolescents of your school have registered to get vaccinated. | |
| Already one third | Already one-third of adolescents of your school has registered to get vaccinated. | |
| Most adolescents | Most adolescents of your school have registered to get vaccinated (80%). | |
| Other countries 80% | In some countries like England and Portugal, more than 80% of adolescents are vaccinated. |
Fig. 1Distribution of decisions made in the DCE. Non-representative sample of 1458 adolescents in France, January–March 2020.
Sensitivity analyses for serial demanders
| Analysis A (n = 599) | Analysis B (n = 543) | Analysis C (n = 634) | Analysis D (n = 508) | |||||
|---|---|---|---|---|---|---|---|---|
| Coef. | 95% CI | Coef. | 95% CI | Coef. | 95% CI | Coef. | 95% CI | |
| Disease | ||||||||
| Respiratory disease | ref | ref | ref | ref | ||||
| Cancer | 0.00 | [-0.11,0.10] | −0.05 | [-0.19,0.09] | −0.01 | [-0.1,0.09] | −0.05 | [-0.21,0.11] |
| Genital warts | −0.04 | [-0.22,0.14] | −0.06 | [-0.24,0.11] | −0.04 | [-0.2,0.12] | −0.06 | [-0.26,0.13] |
| Safety | ||||||||
| No side effect | ref | ref | ref | ref | ||||
| Scientific surveillance | −0.17 | [-0.37,0.04] | −0.13 | [-0.34,0.09] | −0.16 | [-0.36,0.05] | −0.14 | [-0.35,0.08] |
| Other countries | −0.89 | [-1.1,-0.69] | −0.89 | [-1.14,-0.64] | −0.85 | [-1.07,-0.63] | −0.95 | [-1.18,-0.72] |
| Benefit/risk | −1.03 | [-1.31,-0.74] | −1.00 | [-1.29,-0.7] | −0.97 | [-1.27,-0.67] | −1.07 | [-1.35,-0.78] |
| Indirect Protection | ||||||||
| Protects only you | ref | ref | ref | ref | ||||
| Protects other people | −0.01 | [-0.09,0.06] | −0.05 | [-0.16,0.07] | −0.01 | [-0.09,0.06] | −0.05 | [-0.17,0.07] |
| Elimination | 0.10 | [-0.02,0.21] | 0.09 | [-0.06,0.25] | 0.09 | [-0.03,0.21] | 0.10 | [-0.06,0.26] |
| Coverage | ||||||||
| Not enough | ref | ref | ref | ref | ||||
| Already a third | 0.31 | [0.15,0.47] | 0.31 | [0.2,0.43] | 0.29 | [0.14,0.44] | 0.34 | [0.22,0.46] |
| Most adolescents | 0.46 | [0.35,0.58] | 0.46 | [0.39,0.54] | 0.44 | [0.33,0.55] | 0.49 | [0.41,0.58] |
| Other countries 80% | 0.37 | [0.23,0.51] | 0.36 | [0.24,0.48] | 0.35 | [0.21,0.49] | 0.38 | [0.26,0.51] |
A: excluding participants with invariant certainty; B: excluding participants with low response time; C: excluding participants with both invariant certainty and low response time; D: excluding participants with at least one characteristic. *: p-value<0.05; **: p-value<0.01; ***: p-value<0.001.
Sensitivity analyses for vaccine eagerness in the full sample
| Vaccine Eagerness | Analysis A (n = 1340) | Analysis B (n = 1174) | Analysis C (n = 1403) | Analysis D (n = 1111) | ||||
|---|---|---|---|---|---|---|---|---|
| Coef. | 95% CI | Coef. | 95% CI | Coef. | 95% CI | Coef. | 95% CI | |
| Disease | ||||||||
| Respiratory disease | ref | ref | ref | ref | ||||
| Cancer | 0.34 | [-0.05,0.73] | 0.33 | [-0.04,0.70] | 0.34 | [-0.04,0.72] | 0.33 | [-0.04,0.69] |
| Genital warts | −0.14 | [-0.44,0.15] | −0.11 | [-0.37,0.14] | −0.14 | [-0.44,0.15] | −0.11 | [-0.35,0.12] |
| Safety | ||||||||
| No side effect | ref | ref | ref | ref | ||||
| Scientific surveillance | −0.20 | [-0.50,0.09] | −0.30 | [-0.63,0.03] | −0.23 | [-0.52,0.06] | −0.28 | [-0.62,0.07] |
| Safety other countries | −2.18*** | [-2.41,-1.94] | −2.30*** | [-2.59,-2.01] | −2.11*** | [-2.35,-1.87] | −2.39*** | [-2.68,-2.11] |
| Benefit/risk | −2.29*** | [-2.77,-1.81] | −2.30*** | [-2.71,-1.89] | −2.22*** | [-2.69,-1.76] | −2.39*** | [-2.82,-1.95] |
| Indirect Protection | ||||||||
| Protects only you | ref | ref | ref | ref | ||||
| Protects other people | 0.38*** | [0.23,0.54] | 0.32*** | [0.17,0.46] | 0.37*** | [0.22,0.53] | 0.33*** | [0.19,0.47] |
| Elimination | 0.50*** | [0.24,0.75] | 0.52*** | [0.35,0.69] | 0.49*** | [0.25,0.73] | 0.53*** | [0.34,0.71] |
| Coverage | ||||||||
| Not enough | ref | ref | ref | ref | ||||
| Already a third | 0.72*** | [0.34,1.11] | 0.74*** | [0.33,1.15] | 0.71*** | [0.32,1.10] | 0.76*** | [0.36,1.15] |
| Most adolescents | 1.25*** | [0.91,1.59] | 1.33*** | [0.94,1.72] | 1.21*** | [0.89,1.54] | 1.38*** | [0.97,1.79] |
| Other countries 80% | 1.16*** | [0.84,1.49] | 1.17*** | [0.81,1.53] | 1.14*** | [0.8,1.47] | 1.20*** | [0.85,1.55] |
A: excluding participants with invariant certainty; B: excluding participants with low response time; C: excluding participants with both invariant certainty and low response time; D: excluding participants with at least one characteristic. *: p-value<0.05; **: p-value<0.01; ***: p-value<0.001.
Distribution of invariant certainty and short completion time in the sample.
| Acceptable completion time | Short completion time | Completion time missing | Total | |
|---|---|---|---|---|
| Variable certainty | 1,082 | 229 | 29 | 1,340 |
| Invariable certainty | 54 | 55 | 9 | 118 |
| Total | 1,136 | 284 | 38 | 1,458 |
Comparison of Serial demanders, Serial non-demanders and Uniform samples to the Non-Uniform sample.
| Respondents characteristics | Total (n = 1458) | Non-uniform (n = 711) | Uniform (n = 747) | Serial non-demanders (n = 88) | Serial demanders (n = 659) |
|---|---|---|---|---|---|
| Column percentage | |||||
| Age | |||||
| 12–13 years old | 37.7 | 36.9 | 38.6 | 40.9 | 38.2 |
| 14 years old | 47.1 | 48.7 | 45.7 | 42.1 | 46.1 |
| 15–17 years old | 15.2 | 14.5 | 15.8 | 17.1 | 15.6 |
| Gender | |||||
| Girl | 53.5 | 55.7 | 51.4 | 51.1 | 51.4 |
| Boy | 46.5 | 44.3 | 48.6 | 48.9 | 48.6 |
| Middle school ID | ** | *** | |||
| School 1 | 8.0 | 9.4 | 6.6 | 18.2 | 5.0 |
| School 2 | 26.6 | 25.2 | 28.0 | 15.9 | 29.6 |
| School 3 | 10.8 | 12.2 | 9.4 | 22.7 | 7.6 |
| School 4 | 28.0 | 27.4 | 28.5 | 17.1 | 30.1 |
| School 5 | 26.7 | 25.7 | 27.6 | 26.1 | 27.8 |
| Education level of the parents | *** | ||||
| Inferior or equal to French baccalaureat | 19.2 | 19.8 | 18.6 | 17.1 | 18.8 |
| Superior to French baccalaureat for at least one parent | 50.7 | 49.9 | 51.4 | 29.6 | 54.3 |
| I don't know, non-applicable | 30.1 | 30.2 | 30.0 | 53.4 | 26.9 |
| Language spoken with parents | * | * | ** | ||
| Only French | 75.3 | 72.6 | 77.8 | 60.2 | 80.1 |
| Also another language | 24.7 | 27.4 | 22.2 | 39.8 | 19.9 |
| In favour of vaccination (binary) | *** | *** | *** | ||
| Disagree or I don't know | 23.5 | 28.0 | 19.3 | 72.7 | 12.1 |
| Agree or strongly agree | 76.5 | 72.0 | 80.7 | 27.3 | 87.9 |
| Overall stated vaccine status | *** | *** | *** | ||
| Mostly no | 5.7 | 5.4 | 6.1 | 18.2 | 3.6 |
| Mostly I don't know | 72.2 | 68.0 | 76.7 | 69.3 | 67.8 |
| Mostly yes | 22.1 | 26.6 | 17.2 | 12.5 | 28.5 |
| "It is useful to get vaccinated" | *** | *** | |||
| Disagree | 3.2 | 3.6 | 3.0 | 10.2 | 2.0 |
| Agree | 91.9 | 90.5 | 93.3 | 67.1 | 96.8 |
| I don't know | 4.8 | 6.0 | 3.8 | 22.7 | 1.2 |
| "Getting vaccinated can protect others" | *** | ** | |||
| Disagree | 7.2 | 7.8 | 6.6 | 13.6 | 5.6 |
| Agree | 81.9 | 80.5 | 83.2 | 53.4 | 87.2 |
| I don't know | 10.9 | 11.7 | 10.2 | 33.0 | 7.1 |
| "Vaccination scares me because of the needle" | * | ||||
| Disagree | 60.9 | 60.3 | 61.5 | 50.0 | 63.1 |
| Agree | 34.6 | 34.9 | 34.5 | 39.8 | 33.7 |
| I don't know | 4.4 | 4.8 | 4.0 | 10.2 | 3.2 |
| "Vaccination scares me because of the substances in the vaccine" | * | ||||
| Disagree | 64.3 | 62.2 | 66.4 | 54.6 | 67.9 |
| Agree | 24.3 | 26.6 | 22.1 | 30.7 | 21.0 |
| I don't know | 11.4 | 11.2 | 11.5 | 14.8 | 11.1 |
| "Do you find it easy to get trustworthy information on vaccination?" | *** | * | *** | ||
| Difficult | 19.6 | 23.2 | 16.2 | 18.1 | 15.9 |
| Easy | 52.4 | 47.3 | 57.2 | 37.4 | 59.8 |
| I don't know | 28.0 | 29.5 | 26.6 | 44.6 | 24.3 |
NU: non-uniform sample; U: uniform sample; SND: serial non-demanders; SD: serial demanders; *: p-value compared to NU < 0.05; **: p-value compared to NU < 0.01; ***: p-value compared to NU < 0.001. For the overall stated vaccine status: mostly “no” corresponds to a score from 5 to 8, mostly “I don’t know” from 9 to 12, and mostly “yes” from 13 to 15.
Determinants of being a serial non-demander or a serial demander compared to non-uniform respondents. Non-representative sample of 1458 adolescents in France, January–March 2020.
| Total (n = 1458) | Serial non-demanders (n = 88) compared to non-uniform (n = 711) | Serial demanders (n = 659) compared to non-uniform (n = 711) | |||
|---|---|---|---|---|---|
| Column percentage | RRR | 95% CI | RRR | 95% CI | |
| Age | |||||
| 12–13 year old | 37.7 | 1 | 1 | ||
| 14 year old | 47.1 | 0.84 | [0.43; 1.64] | 0.88* | [0.79; 0.99] |
| 15–17 year old | 15.2 | 0.91 | [0.33; 2.47] | 1.12 | [1.00; 1.26] |
| Gender | |||||
| Girl | 53.5 | 1 | 1 | ||
| Boy | 46.5 | 1.25 | [0.98; 1.59] | 1.19** | [1.07; 1.32] |
| Middle school | |||||
| School 1 | 8.0 | 1 | 1 | ||
| School 2 | 26.6 | 0.39*** | [0.36; 0.44] | 2.25*** | [2.01; 2.52] |
| School 3 | 10.8 | 0.78** | [0.66; 0.92] | 1.32*** | [1.27; 1.36] |
| School 4 | 28.0 | 0.35*** | [0.32; 0.38] | 2.17*** | [2.07; 2.28] |
| School 5 | 26.7 | 0.47*** | [0.41; 0.55] | 2.26*** | [2.22; 2.31] |
| Education level of the parents | |||||
| Inferior or equal to French baccalaureat | 19.2 | 1 | 1 | ||
| Superior to French baccalaureat for at least one parent | 50.7 | 1.2 | [0.65; 2.21] | 0.98 | [0.61; 1.57] |
| I don't know, non-applicable | 30.1 | 2.48 | [0.95; 6.50] | 0.93 | [0.77; 1.12] |
| Language spoken with parents | |||||
| Only French | 75.3 | 1 | 1 | ||
| Also another language | 24.7 | 2.46 | [0.78; 7.78] | 0.59 | [0.32; 1.11] |
| Education level of the parents #Language spoken with parents | na | ||||
| Inferior or equal to French baccalaureat #Also another language | na | 1 | 1 | ||
| Superior to French baccalaureat for at least one parent #Also another language | na | 0.48 | [0.15; 1.47] | 1.07 | [0.41; 2.75] |
| I don't know, non-applicable #Also another language | na | 0.66 | [0.15; 2.96] | 1.16 | [0.37; 3.64] |
| In favour of vaccination (binary) | |||||
| Disagree or I don't know | 23.5 | 1 | 1 | ||
| Agree or strongly agree | 76.5 | 0.19*** | [0.13; 0.27] | 2.11*** | [1.51; 2.97] |
| Overall stated vaccine status | |||||
| Mostly I don't know | 5.7 | 1 | 1 | ||
| Mostly no | 72.2 | 3.09 | [0.93; 10.3] | 0.73 | [0.49; 1.08] |
| Mostly yes | 22.1 | 1.43 | [0.80; 2.57] | 1.58* | [1.04; 2.38] |
| "It is useful to get vaccinated" | |||||
| Disagree | 3.2 | 1 | 1 | ||
| Agree | 91.9 | 0.57 | [0.14; 2.24] | 1.3 | [0.65; 2.62] |
| I don't know | 4.8 | 1.09 | [0.34; 3.45] | 0.51 | [0.24; 1.06] |
| "Getting vaccinated can protect others" | |||||
| Disagree | 7.2 | 1 | 1 | ||
| Agree | 81.9 | 0.69 | [0.31; 1.52] | 1.06 | [0.92; 1.22] |
| I don't know | 10.9 | 2.1 | [0.93; 4.73] | 0.78 | [0.44; 1.38] |
| "Vaccination scares me because of the needle" | |||||
| Disagree | 60.9 | 1 | 1 | ||
| Agree | 34.6 | 1.01 | [0.64; 1.61] | 1 | [0.74; 1.34] |
| I don't know | 4.4 | 1.56 | [0.81; 2.99] | 0.84 | [0.44; 1.58] |
| "Vaccination scares me because of the substances in the vaccine" | |||||
| Disagree | 64.3 | 1 | 1 | ||
| Agree | 24.3 | 0.83 | [0.41; 1.66] | 0.93 | [0.79; 1.09] |
| I don't know | 11.4 | 0.76 | [0.31; 1.83] | 1.15 | [0.76; 1.73] |
| "Do you find it easy to get trustworthy information on vaccination?" | |||||
| Difficult | 19.6 | 1 | 1 | ||
| Easy | 52.4 | 1.55 | [0.57; 4.22] | 1.60*** | [1.33; 1.92] |
| I don't know | 28 | 1.37 | [0.64; 2.96] | 1.36* | [1.01; 1.83] |
RRR: Relative Risk Ratios, 95%CI: Confidence interval at the 95%, na: non applicable.
Notes: Estimates obtained from a full multivariate multinomial logistic regression. *: p-value<0.05; **: p-value<0.01; ***: p-value<0.001. For the overall stated vaccine status: mostly no corresponds to a score from 5 to 8, mostly “I don’t know” from 9 to 12, and mostly “yes” from 13 to 15.
Descriptive statistics of the choice certainty level. Non-representative sample of 1458 adolescents in France, January–March 2020.
| Number of choice observations | Mean | Standard Deviation | Q2 (Q1-Q3) | % with constant certainty | % with low mean certainty (0–5) | % with high mean certainty (9–10) | |
|---|---|---|---|---|---|---|---|
| Overall (n = 1458) | 14575 | 7.6 | 2.2 | 8 (6–10) | 8.1 | 7.1 | 21.2 |
| Non-uniform sample (n = 711) | 7105 | 7.2 | 2.3 | 8 (6–9) | 2.7 | 8.3 | 10.7 |
| Uniform sample (n = 747) | 7470 | 8.0* | 2.0 | 8 (7–10) | 13.3* | 6.0 | 31.2* |
| Serial demanders (n = 659) | 6590 | 8.0* | 1.9 | 8 (7–10) | 9.1* | 4.0* | 30.2* |
| Serial non-demanders (n = 88) | 880 | 7.5* | 2.7 | 8 (5–10) | 44.3* | 21.6* | 38.6* |
Notes: n: number of respondents; Q1 = first quartile, Q2 = second quartile, Q3 = third quartile.* P-value test vs non-uniform <0.01. Respondents, including those with unvaried certainty, can have low (0–5), medium (6–8) or high (9–10) mean certainty.
Fig. A.1Certainty distribution among serial non-demanders, serial demanders and non-uniforms..
Impact of attributes on the decision certainty to refuse or accept hypothetical vaccination, among serial non-demanders and serial demanders. January–March 2020.
| Serial non-demanders n = 88 | Serial demanders = 659 | |||
|---|---|---|---|---|
| Certainty | Coefficient | 95%-CI | Coefficient | 95%-CI |
| Disease | ||||
| Respiratory disease | ref | ref | ||
| Cancer | −0.23 | [-0.73,0.27] | −0.01 | [-0.10,0.08] |
| Genital warts | 0.00 | [-0.13,0.12] | −0.04 | [-0.20,0.12] |
| Safety | ||||
| No side effect | ref | ref | ||
| Scientific surveillance | 0.02 | [-0.08,0.13] | −0.15 | [-0.35,0.05] |
| Safety other countries | −0.01 | [-0.22,0.20] | −0.81*** | [-1.02,-0.60] |
| Benefit/risk | 0.07 | [-0.33,0.47] | −0.93*** | [-1.22,-0.65] |
| Indirect Protection | ||||
| Protects only you | ref | ref | ||
| Protects other people | −0.02 | [-0.41,0.38] | −0.01 | [-0.09,0.07] |
| Elimination | 0.09 | [-0.29,0.47] | 0.09 | [-0.03,0.21] |
| Coverage | ||||
| Not enough | ref | ref | ||
| Already a third | 0.11 | [-0.01,0.24] | 0.28*** | [0.14,0.42] |
| Most adolescents | 0.07 | [-0.31,0.44] | 0.42*** | [0.33,0.52] |
| Other countries 80% | 0.20 | [-0.02,0.42] | 0.33*** | [0.20,0.47] |
***: p-value<0.001. Note: clustered standard errors at the school level.
Note: the dependent variable is choice certainty (0–10).
Variability of choice certainty and completion time as quality indicators across subsamples. Non-representative sample of 1458 adolescents in France, January–March 2020.
| Non-Uniform | Uniform | Total | ||
|---|---|---|---|---|
| Serial Demanders | Serial Non-Demanders | |||
| Variability of choice certainty | ||||
| Invariant certainty level | 19 | 60 | 39 | 118 |
| Low variation | 228 | 367 | 32 | 627 |
| High variation | 464 | 232 | 17 | 713 |
| Total | 711 | 659 | 88 | 1458 |
| Completion time | ||||
| Completion time <20th percentile | 129 | 116 | 39 | 284 |
| Completion time ≥20th percentile | 563 | 529 | 44 | 1136 |
| Total | 692 | 659 | 83 | 1420 |
Sensitivity analyses of the effect of attributes on certainty of refusal (0–10) among serial non-demanders, January–March 2020.
| Certainty | Sensitivity analyses for Serial non-demanders | |||||||
|---|---|---|---|---|---|---|---|---|
| Analysis A (n = 49) | Analysis B (n = 49) | Analysis C (n = 67) | Analysis D (n = 31) | |||||
| Coefficient | 95% CI | Coefficient | 95% CI | Coefficient | 95% CI | Coefficient | 95% CI | |
| Disease | ||||||||
| Respiratory disease | ref | ref | ref | ref | ||||
| Cancer | −0.42 | [-1.32,0.49] | −0.12 | [-0.68,0.44] | −0.30 | [-0.96,0.36] | −0.20 | [-1.06,0.67] |
| Genital warts | −0.01 | [-0.22,0.20] | 0.07 | [-0.16,0.31] | −0.01 | [-0.16,0.15] | 0.12 | [-0.25,0.48] |
| Safety | ||||||||
| No side effect | ref | ref | ref | ref | ||||
| Scientific surveillance | 0.03 | [-0.15,0.20] | 0.11*** | [0.05,0.17] | 0.03 | [-0.08,0.15] | 0.18 | [-0.01,0.36] |
| Safety other countries | −0.02 | [-0.38,0.33] | −0.02 | [-0.41,0.36] | −0.02 | [-0.30,0.26] | −0.03 | [-0.61,0.54] |
| Benefit/risk | 0.11 | [-0.65,0.86] | 0.01 | [-0.52,0.54 | 0.10 | [-0.42,0.61] | 0.00 | [-0.83,0.83] |
| Indirect Protection | ||||||||
| Protects only you | ref | ref | ref | ref | ||||
| Protects other people | −0.05 | [-0.74,0.63] | 0.05 | [-0.27,0.36] | −0.03 | [-0.51,0.45] | 0.07 | [-0.44,0.57] |
| Elimination | 0.14 | [-0.56,0.84] | 0.17*** | [0.12,0.21] | 0.12 | [-0.38,0.61] | 0.24*** | [0.17,0.31] |
| Coverage | ||||||||
| Not enough | ref | ref | ref | ref | ||||
| Already a third | 0.19 | [-0.09,0.48] | 0.00 | [-0.17,0.17] | 0.14 | [-0.02,0.29] | −0.01 | [-0.39,0.36] |
| Most adolescents | 0.13 | [-0.60,0.86] | 0.11 | [-0.24,0.47] | 0.09 | [-0.39,0.57] | 0.19 | [-0.39,0.77] |
| Other countries 80% | 0.37 | [-0.08,0.83] | 0.26*** | [0.12,0.39] | 0.26 | [-0.02,0.53] | 0.42*** | [0.23,0.61] |
A: excluding participants with invariant certainty; B: excluding participants with low response time; C: excluding participants with both invariant certainty and low response time; D: excluding participants with at least one characteristic. *: p-value<0.05; **: p-value<0.01; ***: p-value<0.001.
Brief description of middle schools’ characteristics
| Public/Private | REP* | Urban/Rural | |
|---|---|---|---|
| School 1 | Public | Yes | Urban |
| School 2 | Private | No | Urban |
| School 3 | Public | No | Rural |
| School 4 | Public | No | Rural |
| School 5 | Public | No | Urban |
*REP or “Réseaux d’éducation prioritaires” means schools located in deprived areas can beneficiate from a specific educational program aiming at reducing social and territorial inequalities.